Cardiovascular Systems Inc.Find Ratings Reports
CARDIOVASCULAR SYSTEMS INC's gross profit margin for the fourth quarter of its fiscal year 2019 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. CARDIOVASCULAR SYSTEMS INC is extremely liquid. Currently, the Quick Ratio is 3.75 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 10.02% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY19||Q4 FY18|
|Net Sales ($mil)||68.23||59.15|
|Net Income ($mil)||1.47||3.74|
|Balance Sheet||Q4 FY19||Q4 FY18|
|Cash & Equiv. ($mil)||122.67||116.8|
|Total Assets ($mil)||218.58||203.35|
|Total Debt ($mil)||20.97||21.06|
|Profitability||Q4 FY19||Q4 FY18|
|Gross Profit Margin||81.49||83.16|
|Return on Assets||-0.11||0.84|
|Return on Equity||-0.17||1.27|
|Debt||Q4 FY19||Q4 FY18|
|Share Data||Q4 FY19||Q4 FY18|
|Shares outstanding (mil)||34.83||33.36|
|Div / share||0.0||0.0|
|Book value / share||4.25||4.03|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||279693.0||536333.0|
HOLD. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 11.07 indicates a significant premium versus the S&P 500 average of 3.21 and a significant premium versus the subsector average of 8.87. The current price-to-sales ratio is well above the S&P 500 average and above the subsector average, indicating a premium. Upon assessment of these and other key valuation criteria, CARDIOVASCULAR SYSTEMS INC seems to be trading at a premium to investment alternatives.
|CSII NM||Peers 52.45||CSII NA||Peers 35.56|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CSII's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|CSII 223.86||Peers 42.71||CSII NA||Peers 1.16|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
CSII is trading at a significant premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CSII 11.07||Peers 8.87||CSII -140.00||Peers 48.72|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CSII is trading at a premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CSII is expected to significantly trail its peers on the basis of its earnings growth rate.
|CSII 6.60||Peers 6.56||CSII 14.27||Peers 8.26|
Average. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CSII is trading at a valuation on par with its subsector on this measurement.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
CSII has a sales growth rate that significantly exceeds its peers.